News broke this week that the long-awaited FDA review of the deadly chemical abortion drug Mifepristone may not be finished until March of 2027. Many in the pro-life movement, myself included, are upset, rightfully so, as that means that, for the time, there will be no new restrictions on the use or distribution of the […] The post There’s a Reason to be Optimistic About the Delayed FDA Abortion Pill Review appeared first on LifeNews.com .
Kentucky is suing a New York group that advertised illegal abortion drugs at the Kentucky State Fair. The state lawsuit accuses Mayday Health, which bills itself as “a reproductive health education nonprofit,” of “engaging in unfair, false, misleading, or deceptive business practices in viola...
Joe Biden's FDA put abortion pills in the mail with no doctor ever laying eyes on the mother. Pro-life families were promised a federal safety review that would finally slam that...
Pro-life disillusionment with President Trump's second-term record worsens GOP voter enthusiasm gap going into the midterms. "Gold-standard" safety review promised by RFK Jr.
Alliance Defending Freedom Of Counsel Erin Hawley commented regarding the U.S. Food and Drug Administration’s court-ordered update submitted Wednesday on its mifepristone safety study.
The Food and Drug Administration plans to complete its long-awaited review of abortion drugs in mid-December, but the public won’t see the results until March, according to a Wednesday filing from the Justice Department. The 5th Circuit Court ordered the FDA to provide an update on its abortion pill safety review by Oct.
The Food and Drug Administration's safety review of mifepristone is expected to stretch into next year, according to an Oct. 7 court filing, prompting disappointment from pro-life groups.
New York is preparing to destroy about 150,000 abortion pills that expired, a stockpile Gov. Kathy Hochul’s administration bought in 2023 for $112,000.
Since 2016, women's deaths associated with the abortion pill have increased, even as adverse event reports, filed by manufacturers, have dropped. But why?
The FDA says its ongoing safety review of the nation's main abortion pill will continue into next year, a timeline that was quickly condemned by abortion opponents.
The Trump administration said it expects to complete a study of the abortion pill in December and draft a report on the results by March, as it tries to decide how the drug should be made available.
At least 5 innocent Kentucky babies were killed through surgical abortions; however, thousands more were killed in other states or through chemical abortion pills.
The Food and Drug Administration will not finish its safety review of the dangerous abortion pill mifepristone until March 2027, and it will not impose new restrictions before then, the agency said in a court filing Wednesday. That means babies will be killed and women will continue being injured in abortions for months without any […] The post FDA Postpones Review of Dangerous Abortion Pill to March 2027 appeared first on LifeNews.com .
The expected completion timeline is over 2 years after HHS and the FDA promised to study mifepristone's safety & the drug will remain available by mail for now.
The Food and Drug Administration (FDA) won’t publish its safety review of the abortion drug mifepristone until March, it disclosed in a Wednesday court filing, adding that it won’t impose any new restrictions on the pill before that point. The revelations are likely to further anger anti-abortion activists, who have been losing patience with the…
In April 2023, Kathy Hochul stood with Planned Parenthood and promised New York a five-year stockpile of abortion pills. Three and a half years later, New York's Department of Health has...
In 2023, Joe Biden's FDA let abortion pills ship by mail with no in-person doctor's visit. More than a year after the FDA promised a safety review, pro-life leaders say they've...
At FedEx’s annual meeting, the Diocese of Fort Worth, Texas, asked the company to analyze the regulatory and reputational risks of continuing to ship the abortion pill mifepristone into states where abortion is illegal. The post Fort Worth diocese questions FedEx about shipping abortion pills first appeared on Angelus News .
We are four women from four different states. Two of us got abortion drugs online and two in person, but we share one conviction: women deserve to know the risks.
Bishop Michael Olson said he hopes to ‘further the culture of life’ by urging the company to consider whether it’s violating federal law by mailing abortion pills to pro-life states.
The pro-life movement has low expectations ahead of the deadline for the Food and Drug Administration to provide an update on its abortion pill safety review, leaders tell the Daily Signal. “I’m not expecting much,” Tom McCluskey, director of government affairs at CatholicVote, told the Daily Signal.
Bishop Michael Olson said he hopes to “further the culture of life” by urging the company to consider whether it’s violating federal law by mailing abortion pills to pro-life states.
Abstract Mifepristone was first approved in 2000 in conjunction with misoprostol to induce abortion, and both its initial approval and subsequent regulation have been controversial. In 2021, the Food and Drug Administration (FDA) undertook a full review of the mifepristone Risk Evaluation and Mitigation Strategy (REMS) program, with the aim of assessing the necessity of […] The post A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review appeared first on Lozier Institute .
The abortion pill stockpile in New York has expired without distributing a single pill, and Governor Kathy Hochul seemingly does not plan to replace them.
The White House called reports 'completely false' that Attorney General Todd Blanche was told to 'move slowly on any abortion-related actions' because an 'aggressive approach on abortion would generate unwanted attention.'
A new peer-reviewed article on the Food and Drug Administration’s (FDA) 2021 complete review of mifepristone’s Risk Evaluation and Mitigation Strategy (REMS) program provisions found the agency lacked sufficient evidence to justify removal of the in-person dispensing requirement. The paper, authored by Charlotte Lozier Institute (CLI) scholars and published in Issues in Law and Medicine, […] The post Here’s Why the 2021 FDA Review of Mifepristone Was Problematic appeared first on LifeNews.com .
